BRAF and central nervous system cancer: In pediatric low-grade gliomas, including OPGs, aberrations such as BRAF–KIAA1549 fusion and BRAF V600E mutation constitutively activate the MAPK pathway, driving uncontrolled tumor cell proliferation and contributing to treatment resistance.